Table 4.
Comparison of costs and payments after 1 year, relative to rATG
| Cost and Payment Outcomes | Alemtuzumab Match (n=5330 Matched Pairs) | Basiliximab Match (n=9378 Matched Pairs) | ||||||
|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | Matched rATG | Paired Difference (95% CI) | P Value | Basiliximab | Matched rATG | Paired Difference (95% CI) | P Value | |
| 1-yr total cost, $ | ||||||||
| Mean | 86,290 | 88,948 | −2658 (−4648 to −668) | <0.01 | 87,926 | 88,679 | −753 (−2324 to 819) | 0.35 |
| M-estimate | 84,291 | 87,597 | −3083 (−4858 to −1303) | <0.001 | 85,990 | 87,134 | −1058 (−2427 to 313) | 0.13 |
| 1-yr total payment, $ | ||||||||
| Mean | 75,382 | 79,112 | −3729 (−6614 to −844) | 0.01 | 79,589 | 76,814 | 2775 (356 to 5195) | 0.03 |
| M-estimate | 73,500 | 76,346 | −2847 (−5345 to −355) | 0.03 | 76,102 | 74,183 | 1782 (−118 to 3685) | 0.07 |
P values were calculated using the test of the weighted m-statistic for continuous m-estimates and the permutational t test for continuous means. M-estimate, maximum likelihood type estimate.